Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 17

Results For "infectious-diseases"

164 News Found

Novavax announces COVID-19 vaccine booster data indicating four-fold increase in neutralising antibodies
Biotech | August 09, 2021

Novavax announces COVID-19 vaccine booster data indicating four-fold increase in neutralising antibodies

Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series

Sanofi to acquire Translate Bio
Biotech | August 07, 2021

Sanofi to acquire Translate Bio

Advances deployment of mRNA technology across vaccines and therapeutics development

Novavax signs agreement with European Commission for COVID19 vaccine
Biotech | August 05, 2021

Novavax signs agreement with European Commission for COVID19 vaccine

Deal for 100 million doses with additional 100 million through 2023

Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19
News | April 05, 2021

Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19

PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents

Latest Stories

Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr

Sigachi Industries signs MoU with Respilon Group

USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging